US Drug Shortages Trace to Regulation, Not China
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- U.S. drug shortages hit 216 active shortages in 2025, with the op-ed arguing the crisis traces to weakened FDA oversight and domestic consolidation rather than dependence on Chinese pharmaceutical inputs.
- CFR report warnings that China may "deliberately withhold essential pharmaceutical inputs" draw a flawed analogy to critical minerals, since pharmaceutical inputs aren't exhaustible like mined resources—their scarcity reflects profit-driven migration to China.
- FDA regulatory failures have a documented deadly history: the 2008 heparin contamination (150+ adverse events, deaths, Chinese-sourced ingredients) and 2012 fungal meningitis outbreak from a Massachusetts compounding center (750+ patients affected, 64 deaths), with current staffing reductions over the past 18 months weakening oversight further.
- Domestic consolidation leaves the U.S. vulnerable: a single Baxter plant in North Carolina supplied 60% of national IV fluids before Hurricane Helene, forcing emergency imports from the U.K., Canada, and China—yet the CFR report attributes such disruptions to China dependence rather than single-plant reliance.
- Pharmaceutical tariffs scheduled to take effect July 31 could raise drug prices by 11% on average under a 55% tariff, with the CFR suggesting Medicare Part B absorb costs through "more generous hospital reimbursement rates" rather than systemic drug price negotiation.
- NIH funding cuts and politicization of federal research grant approval threaten the publicly funded R&D pipeline that drives pharmaceutical innovation, undermining initiatives like HHS' Operation Trialblazer that aim to boost U.S. R&D competitiveness.
Why it matters: Challenging the dominant national-security framing, the op-ed argues pharmaceutical tariffs effective July 31 could raise drug prices 11% under a 55% rate while ignoring real vulnerabilities: 18 months of FDA staffing reductions, a single Baxter plant supplying 60% of IV fluids, and proposed Medicare Part B reimbursement hikes that would raise premiums and out-of-pocket costs for beneficiaries.
